Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 6:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Astellas Pharma Europe B.V. Clear all

Conditions: Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more

Conditions: Venous Thromboembolism, Arthroplasty, Replacement, Hip
Interventions: YM150, enoxaparin; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 18
States / cities: Phoenix, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 14 more

Conditions: CKD Anemia in Stable Dialysis Patients
Interventions: Epoetin Alfa, Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 74
States / cities: Phoenix, Arizona • Pine Bluff, Arkansas • Chula Vista, California + 58 more

Conditions: CKD Anemia
Interventions: Roxadustat, Placebo; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 55
States / cities: Huntsville, Alabama • Tempe, Arizona • Alhambra, California + 48 more

Conditions: Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 75
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more

Conditions: Diabetes Mellitus, Diabetic Macular Edema
Interventions: ASP8232, ranibizumab, Placebo, Sham intravitreal (IVT) injection; Drug · Other
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 21
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 18 more

Conditions: Prostate Cancer, Pharmacokinetics of Enzalutamide
Interventions: Enzalutamide tablet, Enzalutamide capsule; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: Denver, Colorado • Chicago, Illinois • Pittsburgh, Pennsylvania + 1 more

Conditions: Clostridium Difficile-associated Diarrhea (CDAD)
Interventions: Fidaxomicin oral suspension, Fidaxomicin tablets, Vancomycin oral liquid, Vancomycin capsules; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: Up to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 14
States / cities: Orange, California • Chicago, Illinois • Indianapolis, Indiana + 11 more

Conditions: Systemic Fungal Infections
Interventions: Parenteral micafungin application, Other parenteral antifungal drugs; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: Not listed
Enrollment: 40,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 6
States / cities: Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan + 3 more

Conditions: Neurogenic Detrusor Overactivity, Pediatric
Interventions: Solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 6 Months to 4 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Urinary Bladder, Overactive
Interventions: Solifenacin Succinate Suspension, Placebo, Urotherapy; Drug · Behavioral
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Shreveport, Louisiana • Albany, New York

Conditions: Urinary Bladder, Overactive
Interventions: Solifenacin succinate suspension; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Neurogenic Detrusor Overactivity
Interventions: Solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Tarrytown, New York • Cincinnati, Ohio

Conditions: Diabetes Mellitus, Painful Distal Symmetric Sensorimotor Polyneuropathy
Interventions: Pregabalin, placebo, Training Type A, Training Type B; Drug · Behavioral
Lead sponsor: Analgesic Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: Brighton, Massachusetts • Watertown, Massachusetts • Johnson City, New York + 3 more

Conditions: Anemia in Incident Dialysis Patients
Interventions: Roxadustat, Epoetin Alfa; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 1,043 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Chula Vista, California • La Mesa, California • San Diego, California + 25 more

Conditions: Healthy Volunteers
Interventions: ASP1128, Placebo; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Glendale, California

Search by objective public record fields.

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects